FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385702570> ?p ?o ?g. }

• W4385702570 endingPage "e95480ad" @default.
• W4385702570 startingPage "e95480ad" @default.
• W4385702570 abstract "Topic: 22. Stem cell transplantation - Clinical Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers rapid hematopoietic reconstitution and long-term wellness for aplastic anemia (AA). However, high incidence of acute graft versus host disease (aGVHD) contributed to high treatment-related mortality (TRM). Since AA is a nonmalignant disorder, avoiding aGVHD remains a clinical concern. It has been well documented about the efficacy and safety of ruxolitinib in aGVHD. Aims: Our study aimed to determine the prophylactic value of ruxolitinib for aGVHD in HSCT recipients of AA. Methods: Between August 2021 and December 2022, 26 aplastic anemia patients applied for allo-HSCT were prospectively enrolled in this study at Institute of Hematology and Blood Diseases Hospital, CAMS and PUMC. Patients with HSCT were conditioned including FAC or BFAC regimen. The FAC conditioning regimen was composed of fludarabine (30 mg/m2/d, days -5 to -1), cyclophosphamide (37.5mg/kg/d, days -5 to -2), and rATG (2.5 mg/kg/d, days -5 to -1) or pALG (20 mg/kg/d, days -5 to -1). The BFAC conditioning regimen included busulfan (3.2mg/kg/d, days -7 to -6) on the basis of FAC. All recipients received cyclosporine A or tacrolimus, short-term methotrexate as GVHD prophylaxis. Besides, haplo-identical donor (HID)-HSCT recipients received mycophenolate mofetil consistent with the previous experience. Ruxolitinib was initiated at 5 twice daily until 3 months post-transplantation. Results: This study included 26 AA patients (median age: 32, ranging from 12 to 57) who were diagnosed very severe/severe AA (VSAA/SAA) (n=19), non-severe AA (n=5) and hepatitis-associated aplastic anemia (HAAA) (n=2). The donor type was a matched sibling donor (MSD) in 14 patients and a haploidentical related donor (HID) in 12 patients. With the application of ruxolitinib as prophylaxis, neutrophil and platelet engraftment took a median time of 14.5 (10 – 24) days and 26 (13 – 48) days, respectively, without graft failures (GF) cases observed. Acute GVHD developed in 4/26 patients, including 2 cases of Ⅲ to Ⅳ aGVHD. The 100-day cumulative incidence of severe aGVHD was 3.8±3.77%. In MSD-HSCT group, the incidence of grade II aGVHD was 7.69±7.39%, and no severe aGVHD incidence was documented. HID-HSCT group demonstrated higher cumulative incidence of grade II to Ⅳ aGVHD of 25±12.5% (95%CI 0.000~0.459), and grade Ⅳ aGVHD of 8.33±7.98% (95%CI 0.00~0.227). Three patients developed moderate chronic GVHD (cGVHD) after tapering or stopping ruxolitinib, with the incidence of cGVHD of 11.54%. CMV reactivation developed in 11 patients, and none were diagnosed CMV disease. Epstein-Barr Virus (EBV) infections developed in 2 patients and none of them developed EBV-associated posttransplant lymphoproliferative disorders (PTLD). After a median follow-up of 292 days (95%CI 215.333 to 368.664 days), only one patient in HID-HSCT died of severe sepsis and multi-organ dysfunction. The 2-year overall survival (OS) demonstrated at 95.5 ± 4.5% (95% CI, 0.871~1) at the whole cohort, 100% in the MSD-HSCT group, and 90.9 ± 8.7% (95% CI, 0.754~1) in the HID-HSCT group. Summary/Conclusion: This is the first study investigating the prophylactic application of ruxolitinib for aplastic anemia patients after allo-HSCT. Ruxolitinib would be a promising and safe choice in preventing aGVHD, but this awaits further study in larger cohorts.Keywords: Acute graft-versus-host disease, Allogeneic hematopoietic stem cell transplant, Aplastic anemia" @default.
• W4385702570 created "2023-08-10" @default.
• W4385702570 creator A5015501839 @default.
• W4385702570 creator A5022637765 @default.
• W4385702570 creator A5029862222 @default.
• W4385702570 creator A5032280848 @default.
• W4385702570 creator A5033405514 @default.
• W4385702570 creator A5063880073 @default.
• W4385702570 date "2023-08-01" @default.
• W4385702570 modified "2023-09-27" @default.
• W4385702570 title "P1308: RUXOLITINIB AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN APLASTIC ANEMIA PATIENTS" @default.
• W4385702570 doi "https://doi.org/10.1097/01.hs9.0000972120.95480.ad" @default.
• W4385702570 hasPublicationYear "2023" @default.
• W4385702570 type Work @default.
• W4385702570 citedByCount "0" @default.
• W4385702570 crossrefType "journal-article" @default.
• W4385702570 hasAuthorship W4385702570A5015501839 @default.
• W4385702570 hasAuthorship W4385702570A5022637765 @default.
• W4385702570 hasAuthorship W4385702570A5029862222 @default.
• W4385702570 hasAuthorship W4385702570A5032280848 @default.
• W4385702570 hasAuthorship W4385702570A5033405514 @default.
• W4385702570 hasAuthorship W4385702570A5063880073 @default.
• W4385702570 hasBestOaLocation W43857025701 @default.
• W4385702570 hasConcept C126322002 @default.
• W4385702570 hasConcept C141071460 @default.
• W4385702570 hasConcept C194409129 @default.
• W4385702570 hasConcept C2776112149 @default.
• W4385702570 hasConcept C2776694085 @default.
• W4385702570 hasConcept C2776755627 @default.
• W4385702570 hasConcept C2777408962 @default.
• W4385702570 hasConcept C2777878052 @default.
• W4385702570 hasConcept C2779134260 @default.
• W4385702570 hasConcept C2779263901 @default.
• W4385702570 hasConcept C2779972918 @default.
• W4385702570 hasConcept C2780007613 @default.
• W4385702570 hasConcept C2780076729 @default.
• W4385702570 hasConcept C2780611847 @default.
• W4385702570 hasConcept C2781413609 @default.
• W4385702570 hasConcept C2781440808 @default.
• W4385702570 hasConcept C2911091166 @default.
• W4385702570 hasConcept C71924100 @default.
• W4385702570 hasConcept C90924648 @default.
• W4385702570 hasConceptScore W4385702570C126322002 @default.
• W4385702570 hasConceptScore W4385702570C141071460 @default.
• W4385702570 hasConceptScore W4385702570C194409129 @default.
• W4385702570 hasConceptScore W4385702570C2776112149 @default.
• W4385702570 hasConceptScore W4385702570C2776694085 @default.
• W4385702570 hasConceptScore W4385702570C2776755627 @default.
• W4385702570 hasConceptScore W4385702570C2777408962 @default.
• W4385702570 hasConceptScore W4385702570C2777878052 @default.
• W4385702570 hasConceptScore W4385702570C2779134260 @default.
• W4385702570 hasConceptScore W4385702570C2779263901 @default.
• W4385702570 hasConceptScore W4385702570C2779972918 @default.
• W4385702570 hasConceptScore W4385702570C2780007613 @default.
• W4385702570 hasConceptScore W4385702570C2780076729 @default.
• W4385702570 hasConceptScore W4385702570C2780611847 @default.
• W4385702570 hasConceptScore W4385702570C2781413609 @default.
• W4385702570 hasConceptScore W4385702570C2781440808 @default.
• W4385702570 hasConceptScore W4385702570C2911091166 @default.
• W4385702570 hasConceptScore W4385702570C71924100 @default.
• W4385702570 hasConceptScore W4385702570C90924648 @default.
• W4385702570 hasIssue "S3" @default.
• W4385702570 hasLocation W43857025701 @default.
• W4385702570 hasLocation W43857025702 @default.
• W4385702570 hasOpenAccess W4385702570 @default.
• W4385702570 hasPrimaryLocation W43857025701 @default.
• W4385702570 hasRelatedWork W146568283 @default.
• W4385702570 hasRelatedWork W1966354573 @default.
• W4385702570 hasRelatedWork W2075292277 @default.
• W4385702570 hasRelatedWork W2099377915 @default.
• W4385702570 hasRelatedWork W2244304881 @default.
• W4385702570 hasRelatedWork W2560664961 @default.
• W4385702570 hasRelatedWork W2609272607 @default.
• W4385702570 hasRelatedWork W3083612802 @default.
• W4385702570 hasRelatedWork W3144137627 @default.
• W4385702570 hasRelatedWork W4385702570 @default.
• W4385702570 hasVolume "7" @default.
• W4385702570 isParatext "false" @default.
• W4385702570 isRetracted "false" @default.
• W4385702570 workType "article" @default.